Barclays Maintains Equal-Weight on Insulet, Lowers Price Target to $257
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Matt Miksic has maintained an Equal-Weight rating on Insulet (NASDAQ:PODD) and lowered the price target from $329 to $257.
August 10, 2023 | 11:39 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Barclays has maintained an Equal-Weight rating on Insulet and lowered the price target from $329 to $257.
The lowering of the price target by Barclays indicates a potential decrease in the stock's value. This could lead to a negative short-term impact on Insulet's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100